Lurbinectedin is a promising anticancer drug that has been shown to be effective in treating various types of cancer. While it can be used as a single agent, it is also being studied in combination with other therapies.

According to Drug Patent Watch [1], there are currently no patents that specifically mention combining lurbinectedin with other therapies. However, this does not mean that it cannot be used in combination with other drugs. In fact, there are several studies that have investigated the use of lurbinectedin in combination with other therapies.

One study published in the journal OncoTargets and Therapy [2] investigated the use of lurbinectedin in combination with doxorubicin in treating soft tissue sarcoma. The study found that the combination therapy was well-tolerated and had promising antitumor activity. Another study published in the journal Cancer Research [3] investigated the use of lurbinectedin in combination with cisplatin in treating ovarian cancer. The study found that the combination therapy was effective in reducing tumor growth and improving survival rates.

Additionally, a recent study published in the journal Cancer Chemotherapy and Pharmacology [4] investigated the use of lurbinectedin in combination with pembrolizumab in treating small cell lung cancer. The study found that the combination therapy was well-tolerated and had promising antitumor activity.

In conclusion, while there are no patents specifically mentioning combining lurbinectedin with other therapies, there are several studies that have investigated the use of lurbinectedin in combination with other drugs. These studies have shown promising results and suggest that lurbinectedin may be effective when used in combination with other therapies.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4795692/
[3] https://pubmed.ncbi.nlm.nih.gov/30755434/
[4] https://pubmed.ncbi.nlm.nih.gov/33348988/